ZF2001

Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose

Retrieved on: 
Tuesday, July 20, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Clinical trials, COVID-19 vaccines, Coronaviridae, RNA vaccines, Medicine, Health sciences, COVID-19 vaccine, Medical research, Severe acute respiratory syndrome coronavirus, Rapid Deployment Vaccine Collaborative, ZF2001

The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.

Key Points: 
  • The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.
  • The data suggest a single, adjuvant-free, needle-free intranasal dose of MV-014-212 may provide broad immunity to protect against infection by SARS-CoV-2 and its variants.
  • In NHPs, Meissas intranasal COVID-19 vaccine generated both mucosal and systemic antibodies and was highly protective against wild-type SARS-CoV-2 challenge.
  • We believe Meissas intranasal COVID-19 vaccine has the potential to be an important part of the endgame solution to contain SARS-CoV-2.

American Pharmacists Association Foundation, NOWDiagnostics Launch Nationwide In-Pharmacy Real-Time COVID-19 Antibody Testing with Spike Protein-Targeted, Rapid ADEXUSDx® Test

Retrieved on: 
Monday, July 19, 2021
Medical specialties, Medicine, Branches of biology, Virology, Immunology, Zoonoses, Glycoproteins, Clinical trials, Spike protein, COVID-19, Antibody, ZF2001

The ADEXUSDx COVID-19 antibody test detects antibodies that bind to the receptor binding domain (RBD) subunit of the S1 spike protein of the SARS-CoV-2 virus.

Key Points: 
  • The ADEXUSDx COVID-19 antibody test detects antibodies that bind to the receptor binding domain (RBD) subunit of the S1 spike protein of the SARS-CoV-2 virus.
  • The most protective antibodies develop against this portion of the spike protein S1 domain and are induced by vaccination.
  • The APhA Foundation is affiliated with the American Pharmacists Association, the oldest and largest national professional society of pharmacists in the United States established in 1852.
  • The ADEXUSDxCOVID-19 Test will be distributed by C19 Development, LLC, a wholly owned subsidiary of NOWDiagnostics.

Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference

Retrieved on: 
Thursday, April 8, 2021
Medical specialties, Clinical trials, Vaccination, COVID-19 vaccines, Medicine, Novavax, Medical research, Vaccine, Neutralizing antibody, ZF2001

This event is open to Goldman Sachs clients.

Key Points: 
  • This event is open to Goldman Sachs clients.
  • Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.
  • Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
  • Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

Retrieved on: 
Monday, April 5, 2021
Clinical trials, Medical specialties, COVID-19 vaccines, Medicine, Health sciences, Novavax, Vaccine, Adenoviridae, COVID-19 vaccine, ZF2001

Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax' Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.

Key Points: 
  • Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax' Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.
  • Participants in the South Africa Phase 2b trial will receive either active vaccine for those who initially received placebo, or a booster dose of active vaccine for those who initially received active vaccine.
  • "The crossover arms ensure that all participants have access to an active vaccine candidate while allowing Novavax to continue to monitor the safety and efficacy of our vaccine over the long term," said Filip Dubovsky, M.D., Chief Medical Officer, Novavax.
  • 1 Clinical trial protocols may be found in the Resources section of the Novavax website and will be updated as appropriate.

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

Retrieved on: 
Monday, April 5, 2021
Clinical trials, Medical specialties, COVID-19 vaccines, Medicine, Health sciences, Novavax, Vaccine, Adenoviridae, COVID-19 vaccine, ZF2001

Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax' Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.

Key Points: 
  • Crossover ensures the administration of active vaccine to all participants in the trials and has begun for Novavax' Phase 2b trial in South Africa and its pivotal Phase 3 trial in the United Kingdom.
  • Participants in the South Africa Phase 2b trial will receive either active vaccine for those who initially received placebo, or a booster dose of active vaccine for those who initially received active vaccine.
  • "The crossover arms ensure that all participants have access to an active vaccine candidate while allowing Novavax to continue to monitor the safety and efficacy of our vaccine over the long term," said Filip Dubovsky, M.D., Chief Medical Officer, Novavax.
  • 1 Clinical trial protocols may be found in the Resources section of the Novavax website and will be updated as appropriate.

Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate

Retrieved on: 
Wednesday, March 24, 2021
Clinical trials, Medical research, COVID-19 vaccines, COVID-19 vaccine, Health sciences, Medicine, Adenoviridae, Health, H5N1 clinical trials, ZF2001

The global Phase 2/3 trial is a double-blind, randomized, controlled study of the adjuvanted S-Trimer COVID-19 vaccine candidate in a two-dose regimen, given 21 days apart.

Key Points: 
  • The global Phase 2/3 trial is a double-blind, randomized, controlled study of the adjuvanted S-Trimer COVID-19 vaccine candidate in a two-dose regimen, given 21 days apart.
  • Joshua Liang, Chief Executive Officer of Clover Biopharmaceuticals, said, "Dosing the first participants in SPECTRA marks another significant milestone in our journey to develop a COVID-19 vaccine.
  • Ryan Spencer , Chief Executive Officer of Dynavax, commented, "We are excited to see the first participants dosed in SPECTRA, providing an opportunity for Clover's protein subunit vaccine candidate adjuvanted with CpG 1018 to demonstrate safety and efficacy.
  • We are proud to be collaborating with Clover on the development of this vaccine for COVID-19 and committed to supporting Clover in making the vaccine available globally."

EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea

Retrieved on: 
Thursday, January 21, 2021
Other Manufacturing, Research, Infectious diseases, Hospitals, Clinical trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Medical specialties, Medicine, Health sciences, Medical research, COVID-19 vaccine, Vaccines, Clinical trials, Vaccine, ZF2001, Novavax

EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.

Key Points: 
  • EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.
  • View the full release here: https://www.businesswire.com/news/home/20210121005311/en/
    EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial.
  • The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant.
  • EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.